Economy/Home · Economy

Kolon TissueGene Plunges 16.41%... Falls Below 20,000 Won Intraday but Holds Level at Close

Kolon TissueGene (950160) closed sharply lower in the regular session on the 20th. The 20,000-won level broke during the day, widening volatility. Kolon TissueGene finished trading at 21,650 won, down 4,250 won (16.41%) from the previous session. The stock opened at 27,000 won and rose as high as 2

Oseong Kwon
Staff Reporter
3 min read
Kolon TissueGene Plunges 16.41%... Falls Below 20,000 Won Intraday but Holds Level at Close
CBC News

Kolon TissueGene (950160) closed sharply lower in the regular session on the 20th. The 20,000-won level broke during the day, widening volatility.

Kolon TissueGene finished trading at 21,650 won, down 4,250 won (16.41%) from the previous session. The stock opened at 27,000 won and rose as high as 27,450 won intraday before turning lower and extending its losses. The low of the day was 19,030 won, with the stock even pushed below the 20,000-won mark during the session.

Kolon TissueGene has now posted weakness for three consecutive trading days from the 18th through today. With the decline deepening today amid the losing streak, attention is focused on the stock's price movement.

Particular interest centers on the 20,000-won level. Kolon TissueGene had consistently held above 20,000 won since the intraday session on the 12th, but fell below that level again during today's session. However, the stock recovered part of its intraday losses and defended the 20,000-won level on a closing basis.

With the stock's recent price swings widening, attention is focused on how Kolon TissueGene will trend around the 20,000-won level going forward. Whether it can defend 20,000 won is the key question.

Meanwhile, the KOSDAQ index, where Kolon TissueGene is listed, closed up 1.99% at 840.89.

[This article is not investment advice. All investments are made at the discretion of the individual, and the final responsibility rests with the investor.]

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.